Clinical Trials Logo

Filter by:
NCT ID: NCT00903786 Completed - Clinical trials for Refractory Partial Seizures

A Long-term Extension Study of E2007 in Patients With Refractory Partial Seizures Uncontrolled With Other Anti-Epileptic Drugs (AEDs)

Start date: June 17, 2009
Phase: Phase 2
Study type: Interventional

The purpose of this trial is to investigate the safety and tolerability of perampanel in long- term treatment in the patients with refractory partial epilepsy (uncontrolled with other anti-epileptic drugs) who completed Week 10 of Phase II Study E2007-J081-231 study.

NCT ID: NCT00902174 Completed - Clinical trials for Pulmonary Arterial Hypertension

Imatinib (QTI571) in Pulmonary Arterial Hypertension

IMPRES
Start date: September 2009
Phase: Phase 3
Study type: Interventional

A multinational, multicenter, double blind, placebo-controlled study evaluating the efficacy and safety of imatinib as an add-on therapy in the treatment of patients with severe pulmonary arterial hypertension (PAH).

NCT ID: NCT00901134 Completed - Cardiac Arrest Clinical Trials

Multicenter Registry Study With Therapeutic Hypothermia After Cardiac Arrest in Japan

J-PULSE-HYPO
Start date: June 2008
Phase: N/A
Study type: Observational

Recently, early defibrillation and cardiopulmonary resuscitation (CPR) for sudden onset of cardiac arrest are advancing, however, survival rate is still very low in the world. Furthermore, post-cardiac arrest brain injury is a common cause of morbidity and mortality after successful resuscitation which is urgent issue to be solved. Therapeutic hypothermia is part of a standardized treatment strategy for comatose survivors of cardiac arrest in the metabolic phase usually about 15 minutes after cardiac arrest. However, the evidences of the efficacy of therapeutic hypothermia are still few. The optimal candidates, temperature, the timing of initiation, the therapeutic windows and the rate for rewarming have not been defined clinically and should be established. The purpose of this research is the improvement in the outcomes for patients with coma after resuscitation from out-of-hospital cardiac arrest using therapeutic hypothermia established from the analysis of multicenter registry data.

NCT ID: NCT00898846 Completed - Colorectal Cancer Clinical Trials

Identifying Prognostic Factors in Patients Receiving Tegafur-Uracil for Stage II Colon Cancer That Was Completely Removed By Surgery

Start date: October 2006
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of tumor tissue in the laboratory from patients with cancer may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict which patients will respond to treatment. PURPOSE: This laboratory study is looking at prognostic factors in patients receiving tegafur-uracil for stage II colon cancer that was completely removed by surgery.

NCT ID: NCT00898716 Completed - Neoplasms Clinical Trials

Multiple Ascending Dose Study of BMS-754807 in Patients With Solid Tumors in Japan

Start date: September 2009
Phase: Phase 1
Study type: Interventional

The purpose of this clinical study is to establish the maximum tolerated dose of BMS-754807 when administered orally on a once daily schedule in subjects with solid tumors.

NCT ID: NCT00898326 Completed - Prostate Cancer Clinical Trials

PSA Levels and Biopsy Samples After Implant Radiation and Hormone Therapy in Patients With Stage I or Stage II Prostate Cancer

SHIP36B
Start date: April 1, 2011
Phase: N/A
Study type: Observational

RATIONALE: Studying samples of blood and tissue from patients with prostate cancer after receiving implant radiation therapy and luteinizing hormone-releasing hormone agonist may help doctors identify biomarkers related to cancer and help doctors predict how patients will respond to treatment. PURPOSE: This laboratory study is looking at PSA levels and biopsy samples after undergoing implant radiation therapy and luteinizing hormone-releasing hormone agonist therapy in patients with stage I or stage II prostate cancer.

NCT ID: NCT00897169 Completed - Clinical trials for Diabetes Mellitus, Type 2

A Trial Investigating the Possible Difference in Development of Type 2 Diabetes Between Caucasian and Japanese Subjects

Start date: June 2009
Phase: Phase 1
Study type: Interventional

This trial is conducted in Europe and Japan. The aim of this clinical trial is to investigate the possible difference in the development of type 2 diabetes in a Japanese and a Caucasian population. Healthy subjects, subjects with impaired glucose tolerance, as well as subjects with type 2 diabetes will be included in the trial. The development of type 2 diabetes across the cohort will be investigated with regard to insulin sensitivity and B-cell capacity.

NCT ID: NCT00892749 Completed - Clinical trials for Chronic Kidney Disease

Long-term Study in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

Start date: May 2009
Phase: Phase 3
Study type: Interventional

This is a multi-center, open-labeled, non-comparative study to examine the safety and efficacy of ASP1585 for long-term dosing in chronic kidney disease and hyperphosphatemia patients on hemodialysis.

NCT ID: NCT00892372 Completed - Clinical trials for Type 2 Diabetes Mellitus

Relationship Between Body Weight and Glycohemoglobin

Start date: April 2009
Phase: N/A
Study type: Observational

Control of body weight (BW) is important to prevent and manage type 2 diabetes. Regardless of the close association, little is understood about the precise relationship between BW and glycemic control, which might be of benefit for patients with type 2 diabetes. The researchers investigated the correlation between changes in BW and glycemic control in patients with type 2 diabetes treated with a diet therapy or pioglitazone.

NCT ID: NCT00891332 Completed - Colorectal Cancer Clinical Trials

Study of S-1 Plus LV for Untreated Metastatic Colorectal Cancer

Start date: October 2008
Phase: Phase 2
Study type: Interventional

This is a multicenter study designed to evaluate the response rate of S-1 plus Leucovorin (1 week on and 1 week off) as first -line treatment for patients with metastatic colorectal cancer.